Stock Analysis on Net

Danaher Corp. (NYSE:DHR)

Analysis of Liquidity Ratios
Quarterly Data

Microsoft Excel

Liquidity Ratios (Summary)

Danaher Corp., liquidity ratios (quarterly data)

Microsoft Excel
Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022 Dec 31, 2021 Oct 1, 2021 Jul 2, 2021 Apr 2, 2021 Dec 31, 2020 Oct 2, 2020 Jul 3, 2020 Apr 3, 2020 Dec 31, 2019 Sep 27, 2019 Jun 28, 2019 Mar 29, 2019
Current ratio 1.37 1.43 1.85 1.68 2.26 2.08 1.89 1.89 1.78 1.75 1.68 1.43 1.48 2.26 2.05 1.86 2.08 2.20 1.32 5.19 3.43 2.32 2.18
Quick ratio 0.84 0.85 1.34 1.18 1.76 1.52 1.34 1.30 1.19 1.13 1.08 0.89 0.93 1.67 1.51 1.36 1.52 1.59 0.92 4.68 2.99 1.78 1.58
Cash ratio 0.36 0.35 0.90 0.71 1.31 1.02 0.85 0.71 0.64 0.53 0.49 0.32 0.35 1.07 0.93 0.82 0.94 0.99 0.52 4.04 2.40 1.08 0.84

Based on: 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-27), 10-Q (reporting date: 2019-06-28), 10-Q (reporting date: 2019-03-29).

Liquidity ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Danaher Corp. current ratio deteriorated from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Danaher Corp. quick ratio deteriorated from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Danaher Corp. cash ratio deteriorated from Q1 2024 to Q2 2024 but then slightly improved from Q2 2024 to Q3 2024.

Current Ratio

Danaher Corp., current ratio calculation (quarterly data)

Microsoft Excel
Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022 Dec 31, 2021 Oct 1, 2021 Jul 2, 2021 Apr 2, 2021 Dec 31, 2020 Oct 2, 2020 Jul 3, 2020 Apr 3, 2020 Dec 31, 2019 Sep 27, 2019 Jun 28, 2019 Mar 29, 2019
Selected Financial Data (US$ in millions)
Current assets 10,060 9,609 14,372 13,937 21,205 17,461 16,532 15,883 14,250 13,229 12,670 11,648 10,776 15,392 14,012 13,802 12,541 12,344 11,143 25,597 20,354 11,604 10,080
Current liabilities 7,339 6,701 7,778 8,274 9,367 8,404 8,730 8,389 8,002 7,556 7,547 8,140 7,257 6,825 6,824 7,402 6,038 5,600 8,466 4,932 5,934 5,008 4,633
Liquidity Ratio
Current ratio1 1.37 1.43 1.85 1.68 2.26 2.08 1.89 1.89 1.78 1.75 1.68 1.43 1.48 2.26 2.05 1.86 2.08 2.20 1.32 5.19 3.43 2.32 2.18
Benchmarks
Current Ratio, Competitors2
AbbVie Inc. 0.65 0.81 0.94 0.87 0.96 0.89 0.96 0.96 0.93 0.84 0.82 0.79 1.01 0.91 0.83 0.84 0.95 0.86 3.14 3.18 1.15 0.89 1.04
Amgen Inc. 1.32 1.26 1.42 1.65 2.86 2.77 3.14 1.41 1.68 1.53 1.44 1.59 1.64 1.31 1.66 1.81 2.28 2.18 1.59 1.44 2.89 2.89 2.77
Bristol-Myers Squibb Co. 1.24 1.16 1.11 1.43 1.18 1.39 1.42 1.25 1.42 1.44 1.32 1.52 1.47 1.54 1.56 1.58 1.67 1.47 1.66 1.60 3.83 3.88 1.93
Eli Lilly & Co. 1.27 1.11 1.35 0.94 1.05 1.13 1.30 1.05 1.13 1.10 1.27 1.23 1.30 1.15 1.42 1.40 1.36 1.22 1.11 1.16 1.17 1.13 1.12
Gilead Sciences Inc. 1.14 1.08 1.43 1.34 1.02 1.28 1.29 1.30 1.43 1.48 1.27 1.37 1.36 1.37 1.40 3.25 2.33 3.04 3.10 2.96 3.76 3.62
Johnson & Johnson 1.03 1.07 1.17 1.16 1.21 1.12 1.07 0.99 1.43 1.42 1.39 1.35 1.34 1.39 1.28 1.21 1.48 1.25 1.31 1.26 1.26 1.33 1.44
Merck & Co. Inc. 1.36 1.47 1.25 1.25 1.38 1.28 1.44 1.47 1.46 1.39 1.40 1.27 1.31 1.31 1.02 1.02 1.30 1.32 1.11 1.24 1.26 1.21 1.37
Moderna Inc. 4.09 4.03 3.42 2.46 3.39 3.46 2.73 2.10 1.99 1.77 1.76 1.35 1.24 1.39 1.43 2.43 17.30 9.29 7.89 7.40 6.77 7.17
Pfizer Inc. 1.00 0.86 1.05 0.91 2.38 2.12 1.37 1.22 1.59 1.42 1.39 1.40 1.39 1.37 1.48 1.35 1.40 1.42 1.03 0.88 0.90 1.47 1.54
Regeneron Pharmaceuticals Inc. 5.28 5.44 5.27 5.69 5.18 5.45 5.45 5.06 5.36 5.12 4.76 3.56 3.71 3.57 3.12 3.63 3.89 2.12 4.21 3.67 4.03 3.88 4.58
Thermo Fisher Scientific Inc. 1.63 1.72 1.70 1.75 1.63 1.42 1.27 1.48 1.74 1.65 1.56 1.50 3.19 2.78 2.53 2.13 2.93 2.62 2.32 1.92 1.80 1.49 1.69

Based on: 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-27), 10-Q (reporting date: 2019-06-28), 10-Q (reporting date: 2019-03-29).

1 Q3 2024 Calculation
Current ratio = Current assets ÷ Current liabilities
= 10,060 ÷ 7,339 = 1.37

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Danaher Corp. current ratio deteriorated from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.

Quick Ratio

Danaher Corp., quick ratio calculation (quarterly data)

Microsoft Excel
Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022 Dec 31, 2021 Oct 1, 2021 Jul 2, 2021 Apr 2, 2021 Dec 31, 2020 Oct 2, 2020 Jul 3, 2020 Apr 3, 2020 Dec 31, 2019 Sep 27, 2019 Jun 28, 2019 Mar 29, 2019
Selected Financial Data (US$ in millions)
Cash and equivalents 2,627 2,374 7,031 5,864 12,277 8,575 7,379 5,995 5,150 3,984 3,717 2,586 2,552 7,322 6,330 6,035 5,688 5,539 4,368 19,912 14,252 5,434 3,910
Trade accounts receivable, less allowance for doubtful accounts 3,507 3,298 3,379 3,922 4,201 4,199 4,313 4,918 4,409 4,527 4,407 4,631 4,194 4,103 3,949 4,045 3,496 3,378 3,433 3,191 3,467 3,482 3,409
Total quick assets 6,134 5,672 10,410 9,786 16,478 12,774 11,692 10,913 9,559 8,511 8,124 7,217 6,746 11,425 10,279 10,080 9,183 8,918 7,801 23,104 17,719 8,915 7,319
 
Current liabilities 7,339 6,701 7,778 8,274 9,367 8,404 8,730 8,389 8,002 7,556 7,547 8,140 7,257 6,825 6,824 7,402 6,038 5,600 8,466 4,932 5,934 5,008 4,633
Liquidity Ratio
Quick ratio1 0.84 0.85 1.34 1.18 1.76 1.52 1.34 1.30 1.19 1.13 1.08 0.89 0.93 1.67 1.51 1.36 1.52 1.59 0.92 4.68 2.99 1.78 1.58
Benchmarks
Quick Ratio, Competitors2
AbbVie Inc. 0.44 0.59 0.72 0.63 0.71 0.63 0.66 0.69 0.69 0.61 0.56 0.56 0.75 0.65 0.61 0.60 0.68 0.58 2.88 2.91 0.92 0.64 0.78
Amgen Inc. 0.80 0.75 0.84 0.99 2.41 2.34 2.62 0.95 1.17 0.99 0.90 1.06 1.19 0.86 1.16 1.30 1.65 1.60 1.10 1.01 2.28 2.41 2.37
Bristol-Myers Squibb Co. 0.84 0.78 0.78 1.04 0.77 0.94 1.01 0.87 0.98 1.07 1.03 1.20 1.16 1.16 1.25 1.28 1.43 1.26 1.38 1.26 3.63 3.61 1.64
Eli Lilly & Co. 0.63 0.61 0.68 0.52 0.58 0.63 0.79 0.63 0.71 0.67 0.77 0.80 0.79 0.67 0.83 0.85 0.79 0.68 0.64 0.68 0.66 0.67 0.65
Gilead Sciences Inc. 0.69 0.72 1.06 0.98 0.78 0.95 0.99 0.96 1.06 1.06 0.95 1.01 1.05 0.99 1.08 2.93 2.09 2.78 2.86 2.74 3.41 3.32
Johnson & Johnson 0.70 0.77 0.84 0.82 0.86 0.84 0.81 0.71 1.10 1.09 1.06 1.04 1.03 1.04 0.97 0.91 1.17 0.92 0.98 0.94 0.93 0.95 1.01
Merck & Co. Inc. 0.88 0.88 0.68 0.68 0.83 0.74 0.90 0.93 0.90 0.85 0.84 0.73 0.78 0.75 0.58 0.58 0.77 0.84 0.66 0.78 0.80 0.75 0.88
Moderna Inc. 3.66 3.64 3.15 2.15 2.78 2.87 2.29 1.62 1.55 1.44 1.52 1.21 1.13 1.30 1.37 2.35 17.01 9.10 7.74 7.22 6.64 7.01
Pfizer Inc. 0.56 0.42 0.57 0.50 1.78 1.59 0.88 0.80 1.18 1.02 0.95 1.00 0.99 0.91 0.88 0.78 0.93 0.98 0.60 0.50 0.50 0.71 0.72
Regeneron Pharmaceuticals Inc. 4.34 4.43 4.40 4.82 4.31 4.53 4.54 4.16 4.37 4.20 3.95 2.98 3.03 2.92 2.39 2.86 3.02 1.61 3.38 2.81 3.14 2.99 3.66
Thermo Fisher Scientific Inc. 1.13 1.24 1.19 1.27 1.13 0.89 0.80 1.06 1.06 0.98 0.97 1.00 2.37 1.92 1.70 1.63 2.16 1.83 1.48 1.19 0.97 0.85 0.89

Based on: 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-27), 10-Q (reporting date: 2019-06-28), 10-Q (reporting date: 2019-03-29).

1 Q3 2024 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 6,134 ÷ 7,339 = 0.84

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Danaher Corp. quick ratio deteriorated from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.

Cash Ratio

Danaher Corp., cash ratio calculation (quarterly data)

Microsoft Excel
Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022 Dec 31, 2021 Oct 1, 2021 Jul 2, 2021 Apr 2, 2021 Dec 31, 2020 Oct 2, 2020 Jul 3, 2020 Apr 3, 2020 Dec 31, 2019 Sep 27, 2019 Jun 28, 2019 Mar 29, 2019
Selected Financial Data (US$ in millions)
Cash and equivalents 2,627 2,374 7,031 5,864 12,277 8,575 7,379 5,995 5,150 3,984 3,717 2,586 2,552 7,322 6,330 6,035 5,688 5,539 4,368 19,912 14,252 5,434 3,910
Total cash assets 2,627 2,374 7,031 5,864 12,277 8,575 7,379 5,995 5,150 3,984 3,717 2,586 2,552 7,322 6,330 6,035 5,688 5,539 4,368 19,912 14,252 5,434 3,910
 
Current liabilities 7,339 6,701 7,778 8,274 9,367 8,404 8,730 8,389 8,002 7,556 7,547 8,140 7,257 6,825 6,824 7,402 6,038 5,600 8,466 4,932 5,934 5,008 4,633
Liquidity Ratio
Cash ratio1 0.36 0.35 0.90 0.71 1.31 1.02 0.85 0.71 0.64 0.53 0.49 0.32 0.35 1.07 0.93 0.82 0.94 0.99 0.52 4.04 2.40 1.08 0.84
Benchmarks
Cash Ratio, Competitors2
AbbVie Inc. 0.17 0.31 0.44 0.34 0.38 0.27 0.24 0.31 0.36 0.29 0.23 0.28 0.43 0.30 0.31 0.30 0.33 0.25 2.50 2.56 0.61 0.32 0.38
Amgen Inc. 0.44 0.43 0.49 0.60 2.05 2.00 2.22 0.59 0.80 0.57 0.51 0.66 0.87 0.55 0.82 0.91 1.24 1.09 0.68 0.69 1.94 2.05 2.07
Bristol-Myers Squibb Co. 0.36 0.29 0.37 0.55 0.33 0.43 0.49 0.42 0.48 0.63 0.66 0.78 0.73 0.68 0.75 0.83 1.03 0.92 0.95 0.84 3.10 3.02 0.99
Eli Lilly & Co. 0.14 0.12 0.14 0.11 0.11 0.15 0.23 0.13 0.18 0.18 0.19 0.26 0.28 0.22 0.26 0.29 0.30 0.20 0.14 0.21 0.15 0.20 0.19
Gilead Sciences Inc. 0.26 0.36 0.64 0.57 0.48 0.56 0.57 0.54 0.61 0.62 0.56 0.56 0.64 0.58 0.65 2.52 1.79 2.34 2.50 2.39 3.03 2.97
Johnson & Johnson 0.39 0.47 0.54 0.50 0.53 0.53 0.54 0.42 0.75 0.73 0.70 0.70 0.70 0.65 0.60 0.59 0.79 0.52 0.54 0.54 0.51 0.49 0.53
Merck & Co. Inc. 0.49 0.44 0.22 0.28 0.38 0.27 0.45 0.54 0.49 0.44 0.40 0.34 0.42 0.39 0.26 0.30 0.36 0.50 0.32 0.47 0.39 0.35 0.47
Moderna Inc. 3.59 3.58 2.85 1.73 2.71 2.55 2.01 1.23 1.16 1.09 1.18 0.89 0.90 0.92 1.05 2.22 16.81 9.05 7.71 7.16 6.61 6.97
Pfizer Inc. 0.23 0.16 0.29 0.27 1.42 1.29 0.55 0.54 0.82 0.70 0.61 0.73 0.71 0.61 0.51 0.47 0.64 0.70 0.31 0.26 0.25 0.40 0.39
Regeneron Pharmaceuticals Inc. 2.68 2.80 2.94 3.17 2.75 2.88 2.89 2.46 2.44 2.49 2.34 1.45 1.56 1.05 1.09 1.33 1.29 0.85 1.95 1.53 1.63 1.56 2.14
Thermo Fisher Scientific Inc. 0.46 0.60 0.52 0.58 0.43 0.22 0.22 0.50 0.26 0.17 0.23 0.33 1.55 1.01 0.80 1.00 1.21 0.97 0.54 0.39 0.22 0.30 0.19

Based on: 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-27), 10-Q (reporting date: 2019-06-28), 10-Q (reporting date: 2019-03-29).

1 Q3 2024 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 2,627 ÷ 7,339 = 0.36

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Danaher Corp. cash ratio deteriorated from Q1 2024 to Q2 2024 but then slightly improved from Q2 2024 to Q3 2024.